| P/E (FY) | 19.8 | Sales (TTM) | $700.3M |
| Earnings (TTM) | $461.9M | ROE | 102.75% |
| Net Margin | 72.56% | ROIC | 27.18% |
| Debt / Equity | 0.38 | TD / EBITDA | 1.99 |
| EPS Growth 3Y | — | Sales Growth 3Y | 504.86% |
TG Therapeutics is a commercial-stage biopharmaceutical company focused on acquiring, developing, and commercializing treatments for B-cell mediated diseases in the United States and internationally. It markets BRIUMVI, an anti-CD20 monoclonal antibody for adults with relapsing forms of multiple sclerosis. Its development pipeline includes Ublituximab IV, the BTK inhibitor TG-1701, and the bispecific CD47/CD19 antibody TG-1801, along with additional investigational medicines.
| Market Cap | $8.40B | Trading Days | 3772 |
| 52W High | 59.30 |
| 52W Low | 25.28 |
| % Off High | −7.47% |
| YTD | 84.07% | 1Y | 52.46% |
| 3Y | 178.53% | 5Y | 49.88% |
| 10Y | 769.57% | Since incept. (ann.) | 77.22% |
Product 97% · License 1% · Royalty 1% · Other Revenue 1% · …
| Ann. Volatility (1Y) | 49.65% | Ann. Volatility (3Y) | 68.67% |
| Sharpe (1Y) | 1.11 | Sharpe (3Y) | 0.86 |
| Max Drawdown (1Y) | −27.24% | Max Drawdown (3Y) | −67.71% |
| Beta (3Y, vs SPY) | 1.74 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ALKS | Alkermes plc. | $8.47B | 35.3 |
| PRAX | Praxis Precision Medicines, Inc. | $8.25B | — |
| SYRE | Spyre Therapeutics, Inc. | $8.68B | — |
| PTGX | Protagonist Therapeutics, Inc | $8.80B | — |
| CRNX | Crinetics Pharmaceuticals, Inc. | $8.84B | — |
| NUVL | Nuvalent, Inc. | $9.01B | — |
| LQDA | Liquidia Corp | $7.72B | — |
| IONS | IONIS PHARMACEUTICALS INC | $9.14B | — |
| RYTM | RHYTHM PHARMACEUTICALS, INC. | $7.40B | — |
| CYTK | CYTOKINETICS INC | $9.89B | — |
| SMMT | Summit Therapeutics Inc. | $10.01B |
| — |
| CORT | CORCEPT THERAPEUTICS INC | $10.11B | 114.9 |
